MSH fusion toxin

Drug Profile

MSH fusion toxin

Alternative Names: DAB389 MSH

Latest Information Update: 07 Feb 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seragen
  • Class Antineoplastics
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 07 Feb 2001 Discontinued-Preclinical for Malignant melanoma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top